Drug Trial Radar · NCT07656376
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
465
Planned (sponsor's estimate)
Start
Jun 6, 2027
Primary completion
Feb 7, 2029
Study completion May 8, 2029
Sponsor
- Lead sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I :explores the combination dose and the second phase; Stage II :patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.
Conditions
- Pancreatic Cancer
- Pancreatic Carcinoma
Interventions
DN022150+AG( Stage I )Drug
28-day /cycle
DN022150+AG(Stage II)Drug
28-day /cycle
placebo+AG(Stage II)Drug
28-day /cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: up to 2 years
- PFS as assessed by BICR per RECIST 1.1Time frame: up to 2 years
- OSTime frame: up to 2 years
- ORRTime frame: up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.